Related Experiment Video
Updated: Jan 18, 2026
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
Evaluating hyperbaric oxygen therapy as an adjunct to corticosteroids in sudden sensorineural hearing loss: a
Khaled Moghib1,2, Ali L Abbas Dawoud3, Gergis Altalab4
1Faculty of Medicine, Kasr Al-Ainy, Cairo University, Cairo, Egypt.
Background:
Sudden sensorineural hearing loss (SSNHL) is a medical emergency characterized by unexplained hearing loss, usually one-sided, of at least 30 dB across three or more contiguous frequencies within 72 h. This condition significantly impairs daily communication and has serious consequences for mental health, social relationships, and the overall quality of life. Hyperbaric oxygen therapy (HBOT) is being investigated as a potential adjuvant treatment for SSNHL alongside systemic steroids.
Objectives:
This systematic review and meta-analysis aimed to evaluate the efficacy of HBOT combined with systemic corticosteroids compared with corticosteroids alone in patients with SSNHL.
Method:
We searched PubMed, Cochrane, Scopus, Web of Science, and Google Scholar to identify 14 studies that matched our inclusion criteria of randomized controlled trials (RCTs) published in English, which evaluated HBOT alone or with corticosteroids in adults (≥ 18 years) diagnosed with SSNHL based on the AAO-HNS criteria, reporting pure-tone audiometry (PTA)-based outcomes. The analysis included 794 participants and evaluated outcomes such as improvements in Pure Tone Audiometry (PTA) thresholds, rates of hearing recovery, and adverse events.
Results:
Results indicated that the combined therapy of HBOT and systemic corticosteroids significantly improved low-frequency hearing thresholds (SMD: 0.83, 95% CI: 0.66-1.00, p < 0.0001) and increased the odds of complete recovery (OR: 2.05, 95% CI: 1.41-2.98, p = 0.0002). However, significant heterogeneity (I² = 96.7%) and variations in the treatment protocols were observed. Adverse events, including vertigo, have been reported but are generally mild.
Conclusion:
This meta-analysis suggests that combining systemic corticosteroids with HBOT may improve hearing recovery in ISSNHL, particularly at lower frequencies within the first three months. However, high heterogeneity and the lack of statistical significance in the random-effects model call for cautious interpretation. Well-designed RCTs with standardized protocols and clear patient selection criteria are needed to confirm these findings. Future research should focus on identifying subgroups most likely to benefit and optimizing treatment protocols.
More Related Videos
06:55A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset Callithrix jacchus
Published on: February 27, 2018
09:18A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection
Published on: March 8, 2017
Related Concept Videos
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...